Latham & Watkins Advises Underwriters on PMV Pharma’s Initial Public Offering

Life science focused capital markets team advised the underwriters in the precision oncology company’s offering.

September 25, 2020

PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the pricing of its initial public offering of 11,765,000 shares of common stock at a public offering price of US$18.00 per share.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets deal team led by Bay Area partner Brian Cuneo and New York partner Nathan Ajiashvili, with Bay Area associates Richard Kim, Tess Bloom, and Taimi Jacobson. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associate Barrett Tenbarge; on tax matters by Bay Area partner Grace Lee, with Boston associate Jeremiah Cowen; on intellectual property matters by Bay Area partner Christopher Hazuka, with San Diego associate Robert Yeh; and on benefits and compensation matters by Bay Area partner Ashley Wagner, with Bay Area associate Brianna Stellpflug.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.